Impact of ciprofloxacin in the human-flora-associated (HFA) rat model:: Comparison with the HFA mouse model

被引:32
作者
Perrin-Guyomard, Agnes
Poul, Jean-Michel
Laurentie, Michel
Sanders, Pascal
Fernandez, A. Hayee
Bartholomew, Mary
机构
[1] Agence Francaise Secur Sanit Aliments, Lab Etudes & Rech Medicaments Vet & Desinfectants, F-35302 Fougeres, France
[2] US FDA, Ctr Vet Med, Rockville, MD 20855 USA
关键词
human-flora-associated rodent model; intestinal flora; ciprofloxacin; drug residues;
D O I
10.1016/j.yrtph.2006.02.002
中图分类号
DF [法律]; D9 [法律]; R [医药、卫生];
学科分类号
0301 [法学]; 10 [医学];
摘要
The ecological impact of different doses of ciprofloxacin was investigated in an experimental germ-free rat model into which human fecal flora was inoculated. Animals received oral doses (gavage) of 0, 0.25, 2.5, and 25 mg/kg body weight (bw) of ciprofloxacin once daily for 5 weeks. All doses of ciprofloxacin significantly reduced aerobic populations. Elimination of Enterobacteriaceae and reduction of bifodibacteria were noticed in the group treated with 25 mg/kg of the antibiotic. The rest of the intestinal flora was not affected. These effects were reversible after the treatment ended. The percentage of resistant enterococci increased in rats treated with 2.5 and 25 mg/kg; however, this increase was not statistically significant. There was a significant (P < 0.05) emergence of ciprofloxacin-resistant Bacteroides fragilis group with 25 mg/kg bw, which is equivalent to a human therapeutic dosage of the antibiotic. The MIC values and the percentage of resistance remained elevated 2 weeks after the end of treatment in this anaerobic population. Although sub-populations of enterococci and Enterobacteriaceae showed decreased susceptibility after ciprofloxacin administration, resistance was not evident. The ability of an exogenous strain of Salmonella to colonize the intestine of animals treated with 25 mg/kg of ciprofloxacin confirmed that the drug disrupted the colonization barrier effect of the indigenous flora at the high dose level tested. No changes in the metabolic parameters occurred during the antibiotic treatment. The results obtained in the HFA rat model were similar to those obtained in our previous study using the HFA mice model where ciprofloxacin at 0.125, 1.25, and 12.5 mg/kg bw induced a decrease of enterococci and Enterobacteriaceae populations. The high dose of ciprofloxacin also induced a decrease in bifidobacteria counts, an increase in levels of resistant B. fragilis group and a significant (P < 0.05) disruption of the colonization resistance of the barrier flora in HFA mice. Published by Elsevier Inc.
引用
收藏
页码:66 / 78
页数:13
相关论文
共 36 条
[1]
Comparative activity of moxifloxacin in vitro against obligately anaerobic bacteria [J].
Ackermann, G ;
Schaumann, R ;
Pless, B ;
Claros, MC ;
Goldstein, EJC ;
Rodloff, AC .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2000, 19 (03) :228-232
[2]
BARRIER EFFECT OF NORMAL MICROBIOTA AGAINST CLOSTRIDIUM-DIFFICILE MAY BE INFLUENCED BY DRUGS DEVOID OF ANTIBIOTIC-ACTIVITY [J].
BARC, MC ;
DEPITRE, C ;
CORTHIER, G ;
KARJALAINEN, T ;
BOURLIOUX, P .
MICROBIAL ECOLOGY IN HEALTH AND DISEASE, 1994, 7 (06) :307-313
[3]
Ciprofloxacin at low levels disrupts colonization resistance of human fecal microflora growing in chemostats [J].
Carman, RJ ;
Simon, MA ;
Fernández, H ;
Miller, MA ;
Bartholomew, MJ .
REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2004, 40 (03) :319-326
[4]
*CVM, 2000, CVM UPD CVM PLANS MO
[5]
Effect on the human normal microflora of oral antibiotics for treatment of urinary tract infections [J].
Edlund, C ;
Nord, CE .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 46 :41-48
[6]
*EMEA, 1998, EMEAMLR38898FINAL
[7]
EFFECT OF DIET ON HUMAN FECAL FLORA - COMPARISON OF JAPANESE AND AMERICAN DIETS [J].
FINEGOLD, SM ;
ATTEBERY, HR ;
SUTTER, VL .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 1974, 27 (12) :1456-1469
[8]
Gibaldi M, 1982, Pharmacokinetics, V15
[9]
IMPACT OF RUFLOXACIN AND CIPROFLOXACIN ON THE INTESTINAL MICROFLORA IN A GERM-FREE MICE MODEL [J].
GISMONDO, MR ;
DRAGO, L ;
LOMBARDI, A ;
FASSINA, C ;
CESANA, M .
CHEMOTHERAPY, 1995, 41 (04) :281-288
[10]
GORBACH SL, 1967, GASTROENTEROLOGY, V53, P845